# Nasdaq Biotech Firm 180 Life Sciences Reveals Significant Ethereum Holdings 180 Life Sciences Corp, a biotech company listed on the Nasdaq, has announced it holds a substantial amount of Ethereum (ETH) on its balance sheet. According to the company's latest disclosure, they currently possess 82,186 ETH, valued at approximately $350 million. # Average Purchase Price of $3,806 per ETH The company stated that the average purchase price for their Ethereum holdings is $3,806 per ETH. This investment showcases a growing trend of publicly traded companies diversifying their assets and exploring opportunities within the cryptocurrency market. While the company's primary focus remains in the biotech sector, this ETH allocation could potentially offer additional revenue streams and exposure to the evolving digital landscape. The future direction of this strategy remains to be seen. ```